FMP
KraneShares Emerging Markets Healthcare Index ETF
KMED
AMEX
Inactive Equity
The fund will invest at least 80% of its net assets in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index includes companies that RBICS classifies as engaged in the pharmaceuticals, biotechnology, medical specialties, managed health care, hospital/nursing management, medical/nursing services and services to the health industry businesses. The fund is non-diversified.
18.81 USD
-0.5902 (-3.14%)
Latest KMED News
ETF Trends
Aug 13, 2021
China Calls for Global Cooperation, Pledges 2 Billion Covid-19 Vaccines
The Chinese government has promised 2 billion vaccines to help developing nations in the face of the highly contagious Covid-19 variant delta, as reported by the Wall Street Journal. President XI Jinping pledged the vaccines Thursday, while also calling for greater international cooperation in vaccine export and distribution.
ETF Trends
Jun 15, 2021
Access the Burgeoning Healthcare Sector Overseas with ‘KMED'
Emerging markets (EM) took their lumps from the Covid-19 pandemic, but as these economies re-emerge, look to strength in the healthcare sector with the KraneShares Emerging Markets Healthcare Index ETF (KMED). An increase in healthcare spending could boost the sector as the overall global population starts to age.
ETF Trends
Jun 4, 2021
As WHO Approves Second Chinese Covid-19 Vaccine, ‘KMED' Could Benefit
On Tuesday, the World Health Organization approved a Covid-19 vaccine produced by Sinovac Biotech for emergency use, the second vaccine created in China to be approved according to Reuters. That could be good news for the KraneShares Emerging Market Healthcare Index ETF (NYSE: KMED), which holds several Chinese pharmaceutical stocks.
Benzinga
Dec 10, 2020
3 Emerging Markets ETFs For 2021
One of the asset classes generating plenty of buzz as a 2021 idea is emerging markets. Up 4.5% over the past month, the MSCI Emerging Markets Index is already pricing in that enthusiasm.
SEEKINGALPHA
Apr 24, 2020
FDA cautions on use of malaria drugs for COVID-19 outside of hospitals
In a statement, the FDA is cautioning against the use of malaria meds chloroquine and hydroxychloroquine outside of the hospital setting for the treatment of COVID-19 due to the risk of adverse heart
SEEKINGALPHA
Apr 21, 2020
Coronavirus cases 10x - 20x higher than reported - former FDA Commish
Former FDA Commissioner Scott Gottlieb, M.D. is joining the growing chorus of experts who believe that the actual number of COVID-19 infections in the U.S. is substantially higher than reported, as mu
SEEKINGALPHA
Apr 17, 2020
U.S. COVID-19 testing capacity still constrained - AACC
In a statement, the American Association of Clinical Chemistry (AACC), a clinical laboratory industry group, says the scarcity of essential gear, including sample collection (nasal swabs) and
SEEKINGALPHA
Apr 5, 2020
Malaria drugs in high demand amid COVID-19
States across the U.S. are instituting measures to prevent hoarding of malaria drugs hydroxychloroquine and chloroquine in an effort to maintain supply amid acute demand from pharmacies and COVID-19 p
SEEKINGALPHA
Apr 4, 2020
New York "not ready" for high point of COVID-19 pandemic - Gov. Cuomo
New York Governor Andrew Cuomo is warning that the state is still not ready to handle the peak number COVID-19 cases, expected in the next seven days or so.He says the total number of confirmed cases
SEEKINGALPHA
Apr 2, 2020
FDA relaxes standards for blood donations amid COVID-19
Addressing the "urgent and immediate need" for donated blood during the COVID-19 pandemic, the FDA has issued new guidance relaxing its recommendations for acceptable donations.The deferral pe
